Position in NUVB
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$111,344,543
-$121,207,230 QoQ
Shares Held
25,954,439
0.0% QoQ
Ownership
7.45%
of shares outstanding
% of Portfolio
17.20%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NUVB Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Decheng Capital LLC holds $647,433,708 across 13 Biotechnology names. NUVB ranks #2 (17.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CGON |
CG Oncology, Inc.
|
6,371,669 | $431,234,557 | |
| 2 | NUVB |
Nuvation Bio Inc.
This page
|
25,954,439 | $111,344,543 | |
| 3 | UPB |
Upstream Bio, Inc.
|
2,724,868 | $24,523,812 | |
| 4 | ACRS |
Aclaris Therapeutics, Inc.
|
4,041,736 | $15,156,510 | |
| 5 | AARD |
Aardvark Therapeutics, Inc.
|
3,917,299 | $14,768,217 | |
| 6 | NAMS |
NewAmsterdam Pharma Co N.V.
|
325,057 | $10,405,074 | |
| 7 | RCUS |
Arcus Biosciences, Inc.
|
477,819 | $10,320,890 | |
| 8 | RVMD |
Revolution Medicines, Inc.
|
93,500 | $9,092,875 |
All Filings in NUVB
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $111,344,543 | 25,954,439 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $232,551,773 | 25,954,439 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $96,031,424 | 25,954,439 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $50,611,156 | 25,954,439 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $45,679,812 | 25,954,439 | Shares | Sole | 2025-05-08 | |
| 2024-12-31 | $69,038,807 | 25,954,439 | Shares | Sole | 2025-02-14 | |
| 2024-09-30 | $59,435,665 | 25,954,439 | Shares | Sole | 2024-11-15 | |
| 2024-06-30 | $20,294,697 | 6,950,239 | Shares | Sole | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||